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Abstract
The current available insulin therapies decrease blood glucose but are associ-
ated with the risk of developing hypoglycemia. Glucagon is a counter regula-
tory hormone and we hypothesize that a fixed ratio of insulin and a long-
acting glucagon-analogue can reduce the risk of hypoglycemia. To define an
appropriate ratio we tested two fixed glucagon doses (3.5 and 10 nmol/kg) in
combination with increasing doses of insulin in diabetic rats. We observed a
plateau in blood glucose at 15.2 mmol/L with 10 nmol/kg of the glucagon-
analogue. The mechanism behind this plateau, protecting against hypo-
glycemia, was investigated by measuring the glucose output, cAMP produc-
tion, and hormone binding in primary rat hepatocytes. While glucose output
could contribute to the observed plateau in blood glucose, cAMP response or
hormone binding did not explain the observation. Though such plateau indi-
cated decreased risk of hypoglycemia a full normalization of blood glucose
was still needed. Based on the data obtained with 3.5 nmol/kg of the gluca-
gon-analogue, a 1:23 (glucagon-analogue:insulin) ratio was chosen and a
dose-response was performed in diabetic rats. At low doses (≤20 nmol/kg),
insulin and the 1:23 ratio showed similar efficacy of lowering blood glucose.
Interestingly, the insulin-dose resulting in hypoglycemia was increased from
40 nmol/kg insulin alone to 160 nmol/kg insulin in the 1:23 ratio. Analysis of
the liver glycogen content at the end of the experiment showed that the high-
est dose in the 1:23 ratio almost emptied the liver from glycogen. Thus, liver
glycogen is essential for the protective effect of glucagon in hypoglycemia.
Introduction
Insulin and glucagon are counteracting hormones in reg-
ulation of blood glucose (Cryer 1993). Insulin lowers
blood glucose, while glucagon increases blood glucose.
For many years, insulin has been a vital part of diabetes
treatment. However, although insulin therapies decrease
blood glucose, they are also associated with the risk of
developing hypoglycemia. American Diabetes Association
and European Association for the Study of Diabetes
define clinically significant hypoglycemia as blood glucose
levels below 3.0 mmol/L (Group IHS, 2016). Hypo-
glycemia results in a range of symptoms progressing from
sweating and hunger to cognitive dysfunction and seizures
(Cryer et al. 2003). Furthermore, hypoglycemia has been
associated with increased risk of cardiovascular events
and mortality (Ismail-Beigi et al. 2010; Khunti et al.
2015). Thus, the fear of hypoglycemia is a major limiting
factor in the glycemic control of diabetes (Cryer 2002). In
order to reduce the hypoglycemic risk, some patients
maintain their blood glucose concentrations above the
recommended levels (Anderbro et al. 2015). The resulting
poor metabolic control is associated with an increased
risk of future diabetic complications. Therefore, hypo-
glycemia needs to be addressed for better management
and treatment of patients with diabetes.
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Usually counter regulatory responses, such as secretion
of glucagon and adrenaline, oppose the effects of insulin
when the blood glucose concentration falls below
3.9 mmol/L (Sprague and Arbelaez 2011). However, it is
well known that these counter regulatory responses to
hypoglycemia are gradually lost in both type 1 diabetes
and advanced type 2 diabetes (Cryer et al. 2003). On
account of these defects, insulin therapy alone is unlikely
to achieve ideal control and safety. In order to improve the
glycemic control a dual hormone therapy may be needed.
Today, glucagon is only used to treat severe insulin-
induced hypoglycemia in diabetes. The closed-loop
artificial pancreas, imitating normal physiology by adminis-
tering either insulin or glucagon, demonstrates the feasibil-
ity of a safe blood glucose regulation in individuals with
type 1 diabetes (Ward et al. 2008; El-khatib et al. 2010; Hai-
dar et al. 2013). Thus, several studies have shown a benefi-
cial effect of glucagon in reducing the risk of hypoglycemia
in insulin therapies. Opposed to the artificial pancreas,
which administers either insulin or glucagon depending on
the blood glucose level, we investigated whether coadminis-
tration of a fixed ratio of the two hormones could reduce
the risk of hypoglycemia when treating diabetic rats.
Materials and Methods
Compounds and formulations
NPH insulin (Novo Nordisk A/S) was used for daily
treatment in diabetic rats. For in vivo experiments,
human insulin (Novo Nordisk A/S), and a long-acting
glucagon-analogue (Novo Nordisk A/S) were used. Both
were formulated in 5 mmol/L phosphate, 140 mmol/L
NaCl, 70 ppm polysorbate-20, pH 7.4. For in vitro exper-
iments human insulin (Novo Nordisk internal reference
solution) and native glucagon (Novo Nordisk A/S) dis-
solved in 20% H2O and 80% DMSO were used.
Rat hepatocytes
Hepatocytes from ad libitum-fed male Sprague-Dawley
rats ( 200 g) were isolated in situ by a two-step perfu-
sion technique (Seglen 1976; Andersen et al. 1999). Cell
viability, determined with a NucleoCounter (Chemome-
tec), was consistently greater than 85%. Hepatocytes were
diluted to a cell density of 0.5 9 106 cells/mL in basal
medium (Medium 199 (Gibco #41150, Thermo Fisher
Scientific) supplemented with 100 nmol/L dexametha-
sone, 1% penicillin streptomycin (Gibco #15140-122,
Thermo Fisher Scientific) and 1 nmol/L insulin with 4%
FBS (Gibco #26140, Thermo Fisher Scientific) and plated
in collagen-coated plates (400 lL in 24 well plates for
glycogenolysis and 100 lL in 96 well plates for cAMP and
binding assay). To remove dead cells, the medium was
changed to basal medium with 0.1% FBS 3 h after initial
plating. The competition binding and cAMP measure-
ments were performed on the next day. For glycogenolysis
experiments, the medium was changed after 24 h to basal
medium supplemented with 0.1% FBS, 9.5 mmol/L glu-
cose and 9 nmol/L insulin, and experiments were then
performed on day 3.
Glycogenolysis
The hepatocytes were washed twice in PBS without CaCl2
and MgCl2 (Gibco #14190-094, Thermo Fisher Scientific)
prior to preincubation for 30 min at 37°C in medium
199 without glucose (Gibco #041-94001M, Thermo Fisher
Scientific). They were then stimulated for 1 h at 37°C
with increasing ligand (glucagon and/or human insulin,
Novo Nordisk A/S) concentrations (0–1 lmol/L).
Glycogenolysis was measured as glucose released into the
medium using a glucose oxidase kit (BioVision #K606-
100). These data were plotted as dose-response curves
and normalized to the maximum response generated from
the stimulation with glucagon.
cAMP production
The hepatocytes were washed twice in HBSS buffer (HBSS
with CaCl2 and MgCl2 (Gibco #14025, Thermo Fisher Sci-
entific) supplemented with 10 mmol/L HEPES (Sigma-
Aldrich #H3375)) prior to preincubation for 30 min at
37°C in HBSS buffer in addition of 0.1% pluronic (Gibco
#24040-032, Thermo Fisher Scientific) and 500 lmol/L
IBMX (Sigma-Aldrich #I7018-100MG, dissolved in
DMSO). The hepatocytes were then stimulated for
30 min at 37°C with increasing ligand (glucagon and/or
human insulin, Novo Nordisk A/S) concentrations
(0–1 lmol/L). After aspiration of the ligands, the cells were
lysed immediately in cold lysis buffer for 10 min. The
lysates were transferred to a 384 well optiplate and detect-
ing reagents provided in the kit (cAMP dynamic 2, Cisbio
Bioassays, Codolet, France) were added. After incubation
in the dark at room temperature for 2 h, the signal of fluo-
rescence resonance energy transfer was read using the Envi-
sion 2104 Multilable Reader. The concentration of cAMP
produced was interpolated from a standard curve (pre-
pared according to the kit). These data were plotted as
dose-response curves and normalized to the maximum
response generated from stimulation with glucagon.
Whole-cell radioligand binding assay
The hepatocytes were washed twice in HBSS buffer prior
to preincubation for 30 min on ice in assay buffer (HBSS
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buffer supplemented with 0.1% pluronic and 1% ovalbu-
min (Sigma-Aldrich #A5503)). The hepatocytes were
incubated overnight at 4°C with 60 pmol/L 125I-glucagon
(Novo Nordisk A/S) or 125I-insulin (Novo Nordisk A/S)
and increasing concentrations of unlabeled glucagon or
insulin. Unbound ligand was washed off, and the cells
were lysed in 0.1 M NaOH prior to addition of Micro-
Scint-40. The radioactivity was measured as cpm in a
TopCount NXT gamma counter (PerkinElmer Life
Sciences).
Experimental animals
Male Sprague-Dawley rats (300 g.) were obtained from
Taconic, Lille Skensved, Denmark. All animals were group
housed with a 12-h dark/light cycle and had free access to
food and water. All rats had at least 1 week of acclimati-
zation before induction of diabetes. The experiments were
approved by the Danish Animal Experiment Inspectorate,
under Danish Ministry of Justice, and are in accordance
with the Danish Animal Experimentations Act. The stud-
ies were performed in the Laboratory Animal Facility at
Novo Nordisk A/S, Maaloev, Denmark.
Streptozotocin-induced diabetes
On the day of treatment, preweighed STZ (Sigma-
Aldrich) was dissolved in 0.1 mol/L cold citric acid buffer
(65 mg/mL, pH 4.5). Diabetes was induced in isoflurane-
sedated rats by injection of 65 mg/kg STZ. The following
days, regular inspections were performed and from day 3
the rats were dosed subcutaneously with NPH insulin
(Novo Nordisk A/S, 600 lmol/L, 3U/rat/day). Experi-
ments were performed between 2 and 5 weeks after STZ
treatment. Only rats with basal blood glucose levels above
15 mmol/L were included.
Study designs
All experiments were performed in nonfasted diabetic
rats. The rats were randomly assigned to dosing groups.
In one set of experiments the rats were dosed subcuta-
neously (1 mL/kg) with insulin alone (0–40 nmol/kg) or
insulin (up to 160 nmol/kg) in combination with fixed
doses of glucagon (10 nmol/kg or 3.5 nmol/kg). In
another set of experiments, the rats were dosed subcuta-
neously with insulin alone (0–40 nmol/kg) or with a fixed
1:23 (glucagon-analogue:insulin) ratio. Blood glucose was
measured repeatedly for 6 h. Rats with symptomatic
hypoglycemia received oral glucose and were excluded
from data analysis. At the end of one of the experiments
with fixed 1:23 ratio, the rats were anesthetized (5%
isoflurane) and liver samples were collected, freeze
clamped in liquid nitrogen, and stored at 80°C until
analysis of glycogen content.
Blood glucose measurements
To assess the maximum blood glucose lowering effect,
blood from the tail vein (10 lL) was collected in capillary
tubes and transferred to 500 lL system-solution. Blood
glucose levels were analyzed using the glucose oxidase
method at a Biosen glucose analyzer (EKF Diagnostics,
Barleben, Germany) according to manufacturer’s instruc-
tions.
Determination of liver glycogen content
Approximately 30–40 mg of frozen liver tissue was
homogenized in 1 mL sodium acetate buffer (0.15 mol/L,
pH 4.9) supplemented with Triton X-100 (0.75%). The
tissue homogenate was heated to 100°C for 2 min, cooled
on ice and mixed thoroughly. The homogenate was then
divided in two; one part for measurement of free glucose
concentration and a second part for measurement of total
glucose concentration. For measurement of free glucose,
the homogenate was centrifuged at 9000 G for 10 min
before the supernatant was collected and stored at
20°C. For measurement of total glucose concentration,
the homogenate was incubated with amyloglucosidase
(Sigma-Aldrich A1602) overnight at room temperature
before centrifugation and collection of the supernatant.
The total and free glucose concentrations were measured
using the Cobas 6000 analyzer (Roche). The glycogen
content in the tissue samples was then calculated by
subtracting the free glucose from the total glucose
concentrations.
Statistics
GraphPad Prism was used to fit and analyze the data.
Multiple t-tests were used to compare two mean values.
Prism computed an unpaired t-test for each row, followed
by multiple comparisons using the Holm-Sidak method.
For comparison of three or more mean values, a one-way
analysis of variance (ANOVA) followed by Tukey’s multi-
ple comparisons test was used. A P value below 0.05
reflects a statistically significant difference.
Results
Insulin in combination with fixed doses of
glucagon in diabetic rats
To define an appropriate glucagon:insulin ratio for future
experiments two glucagon doses (10 and 3.5 nmol/kg) in
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 6 | e13657
Page 3
C. Pedersen et al. A Fixed Ratio of Glucagon and Insulin
combination with increasing doses of insulin (0–40 nmol/
kg) were tested in diabetic rats. The effect was evaluated
by looking at the lowest blood glucose values measured
during the 6-h experiments. In two individual experi-
ments (Fig. 1A and B), insulin alone lowered blood glu-
cose levels in a dose-dependent manner from
23.9  1.9 mmol/L to 3.8  0.7 mmol/L and from
26.6  0.8 to 3.4  0.6 mmol/L, respectively. The long-
acting glucagon-analogue did not result in a significant
change in blood glucose on its own (data not shown).
However, in combination with insulin 10 nmol/kg of the
glucagon-analogue decreased the glucose lowering effect
of insulin resulting in a plateau at 15.2  1.7 mmol/L for
insulin doses of 10, 20, and 40 nmol/kg (Fig. 1A). In
combination with 10 nmol/kg of the glucagon-analogue,
there was no significant difference in the blood glucose
lowering effect of 5 nmol/kg insulin and 40 nmol/kg
insulin. A similar plateau in blood glucose was not seen
with the 3.5 nmol/kg dose of the glucagon-analogue in
combination with insulin (Fig. 1B). In combination with
3.5 nmol/kg of the glucagon-analogue, 40 nmol/kg insulin
lowered the blood glucose significantly compared to
5 nmol/kg insulin (P = 0.013).
Glycogenolysis, radioligand binding, and
cAMP in rat hepatocytes
To understand the mechanism of the observed plateau in
blood glucose we measured glycogenolysis in primary rat
hepatocytes. As expected, glucagon stimulated glucose
output from the hepatocytes in a dose-dependent manner
with a logEC50 of 9.34 logM (~0.5 nmol/L) (Fig. 2A).
Insulin alone did not have any significant effect on the
glucose output. However, in combination with 1 nmol/L
glucagon insulin showed a biphasic response. At low con-
centrations (<10 nmol/L) insulin inhibited glucose output
from the hepatocytes, but at higher concentrations it
stimulated glucose output (Fig. 2A). As illustrated in Fig-
ure 2B, 10 nmol/L insulin significantly inhibited the glu-
cagon-induced glucose output (P < 0.0001), whereas
1000 nmol/L insulin significantly stimulated the gluca-
gon-induced glucose output (P = 0.0012). Even though,
this challenges the general view of the opposing interplay
between insulin and glucagon, it could potentially explain
the observed plateau in blood glucose (Fig. 1A).
Whole-cell radioligand binding on primary rat hepato-
cytes was used to clarify whether the interplay between
insulin and glucagon was happening at the level of recep-
tor binding. As expected from the molecular differences
in the receptors of these two hormones, insulin neither
displaced nor enhanced binding of glucagon to the gluca-
gon receptor. Similarly, glucagon neither displaced nor
enhanced binding of insulin to the insulin receptor
(Fig. 3). This indicates that insulin does not bind to the
glucagon receptor and vice versa. Consequently, the
enhanced glycogenolysis observed at high concentrations
of insulin was not mediated by an increased binding of
glucagon to its receptor in the presence of insulin.
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Figure 1. Insulin in combination with fixed doses of glucagon in diabetic rats. The lowest1 blood glucose value (mmol/L) obtained during the 6-h
experiments plotted as function of insulin dose (log nmol/kg). (A) Dose-response of insulin  10 nmol/kg glucagon-analogue. (B) Dose-response of
insulin  3.5 nmol/kg glucagon-analogue. The solid black lines represent the insulin dose-response curves (0–40 nmol/kg). The dotted black lines
represent similar doses of insulin in the presence of the glucagon-analogue. All data are expressed as means  SEM; n = 6 per group. * indicate
significant difference between “5 nmol/kg insulin + 3.5 nmol/kg glucagon-analogue” and “40 nmol/kg insulin + 3.5 nmol/kg glucagon-
analogue” (P = 0.013), (analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test). 1The points corresponding to 0 nmol/kg
insulin are basal blood glucose levels from the “vehicle group” and the “glucagon-analogue group”, respectively.
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Glucagon is known to stimulate glucose output through
a cAMP-dependent mechanism (Christophe 1995; Jiang
and Zhang 2003). Thus, to investigate the interplay at a
downstream level, the cAMP response was measured in pri-
mary rat hepatocytes. Glucagon stimulated cAMP produc-
tion in a dose-dependent manner with a logEC50 of 7.94
logM (~10 nmol/L) (Fig. 4). Insulin in combination with
either 1 nmol/L or 10 nmol/L glucagon resulted in cAMP
production corresponding to the effect of the fixed
glucagon doses. Insulin did not have any additional effect
on the cAMP production (Fig. 4). Hence, the observed pla-
teau in blood glucose and the stimulatory effect of insulin
on the glucagon-induced glucose output occurs through a
cAMP-independent mechanism.
A fixed ratio of glucagon and insulin in
diabetic rats
Driven by the protective effect of dual treatment with insu-
lin and glucagon on hypoglycemia (Fig. 1), we went on to
determine the optimal ratio between the two hormones. An
optimal ratio would provide full normalization of blood
glucose with additional benefit of reduced hypoglycemic
risk. In order to do this, we increased the insulin dose (up
to 160 nmol/kg) in combination with 3.5 nmol/kg of the
glucagon-analogue. Again, insulin alone (0–40 nmol/kg)
lowered blood glucose levels in a dose-dependent manner
from 23.1  1.0 to 2.7  0.4 mmol/L (Fig. 5). The addi-
tion of 3.5 nmol/kg of the glucagon-analogue resulted in a
right-shift of the insulin dose-response curve and a subse-
quent decreased potency of insulin. An insulin-dose of
80 nmol/kg in combination with 3.5 nmol/kg of the gluca-
gon-analogue only lowered blood glucose to 6.5 
2.0 mmol/L, a level that was reached by 10 nmol/kg insulin
in the absence of the glucagon-analogue (Fig. 5). This ratio
corresponding to 1:23 (glucagon-analogue:insulin) was
chosen and a dose-response experiment was performed in
diabetic rats. An expected dose-response was observed for
0–40 nmol/kg insulin alone (Fig. 6A). In the 1:23 ratio the
insulin dose administered ranged from 5 to 160 nmol/kg,
and a shift in lowest blood glucose value towards later time
points was observed (Fig. 6B). There was no significant
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difference between the maximum blood glucose lowering
effect of 5, 10, and 20 nmol/kg insulin alone and the 1:23
ratio (Fig. 6C). This indicates similar potency of insulin
alone and the 1:23 ratio in the dose-range normalizing
blood glucose. However, with a higher dose of insulin
(40 nmol/kg) in combination with the glucagon-analogue
(1.8 nmol/kg) a significant (P < 0.05) increase in blood
glucose was observed (Fig. 6C and D). This indicates a pro-
tective effect of glucagon against hypoglycemia. The insu-
lin-dose resulting in hypoglycemia was increased four
times: from 40 nmol/kg insulin alone to 160 nmol/kg insu-
lin in the presence of the glucagon-analogue (Fig. 6C).
After the experiment liver samples were collected and
the amount of glycogen was determined. Glucagon stimu-
lated glycogenolysis as indicated by reduced glycogen
stores in the liver with increasing doses of glucagon in
the 1:23 ratio (Fig. 7). The amount of glycogen was
reduced from 142  36 lmol/g in the vehicle-treated
group to 5.2  0.8 lmol/g with the highest dose in the
1:23 ratio (7 nmol/kg glucagon + 160 nmol/kg insulin).
Discussion
We hypothesized that coadministration of glucagon and
insulin could reduce the risk of hypoglycemia when treat-
ing diabetes. In rats, when trying to define an ideal ratio we
observed a plateau in blood glucose after administering a
fixed dose of a long-acting glucagon-analogue in combina-
tion with increasing doses of insulin (Fig. 1A). Extending
this curve would probably confirm the observed plateau.
However, since the plateau was around 15 mmol/L and we
aimed for a treatment that could normalize blood glucose,
we found it redundant and unethical to waste animals in an
extended experiment. Nevertheless, we found it interesting
and investigated the mechanism behind the plateau by
measuring glycogenolysis in primary rat hepatocytes. The
results indicated that insulin in combination with glucagon
had a biphasic response (Fig. 2A); at concentrations below
10 nmol/L insulin inhibited glucose output from the hepa-
tocytes opposed to insulin concentrations above 10 nmol/L
which stimulated glucose output from the hepatocytes.
Despite this being in contrast to the general understanding,
where insulin and glucagon are only considered as counter-
acting hormones, it could potentially explain the observed
plateau in blood glucose. Other investigations of the inter-
play between insulin and glucagon have focused on the
effects at more physiological concentrations (Cherrington
et al. 1976; Cherrington 1999). The basal insulin concentra-
tion in plasma is individual, but typically around 60 pmol/
L in fasted state (Keith 2010). Though, it oscillates in line
with food intake up to 800 pmol/L (K€onig et al. 2012). The
action of the two hormones at supra-physiological concen-
trations has been studied to a very limited extent. An insu-
lin concentration of 10 nmol/L has been shown to suppress
glucagon-stimulated glucose production in men (Bomboy
et al. 1977). Similar results have been obtained when look-
ing at liver perfusion in vitro (Mackrell and Sokal 1969).
However, in our case the stimulation of glucose output
from the hepatocytes was only observed at insulin concen-
trations above 10 nmol/L and thus never reported before.
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Such a high concentration of insulin may seem unrealistic
and therefore probably not investigated or overlooked by
others. Importantly, our studies show that the conventional
understanding of the counteracting regulation of blood
glucose by insulin and glucagon appears to count only for
physiological, but not pharmacological, concentrations of
the two hormones. At supra-physiological concentrations,
a biphasic curve appears for insulin with enhanced effect of
glucagon-induced hepatic glucose output (Fig. 2A); a phe-
nomenon that was not explained by receptor cross-reactiv-
ity (Fig. 3) or amplification of glucagon-induced cAMP
production (Fig. 4). In contrast to the glucagon receptor,
which is a G protein-coupled receptor, the insulin receptor
activates G protein-independent pathways, and hence do
not per se elicit a cAMP response. Accordingly we find that
the stimulatory effect of insulin on the glucagon-induced
glucose output occurs through a cAMP-independent mech-
anism. Yet the mechanism remains to be identified. We
have looked at other signaling targets involving phosphory-
lation of cAMP response element-binding protein and acti-
vation of phospholipase C, but those did not give any
glucagon response in primary rat hepatocytes (data not
shown). Despite the lacking mechanistic understanding we
find the phenomenon interesting and the data important to
share. Other techniques (e.g., phospho-proteomics) are
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more suitable for identification of pathways behind the
mechanism. That would, however, require much more
resources and was out of the scope in this study.
Our goal was to find a fixed ratio of glucagon and insulin
which could combine the ability to normalize blood glu-
cose with reduced risk of hypoglycemia in diabetic rats.
Increasing doses of insulin in combination with 3.5 nmol/
kg of the glucagon-analogue could normalize blood glu-
cose. Therefore, these data were used to define the fixed
1:23 ratio of glucagon and insulin. At low doses
(≤20 nmol/kg insulin), the 1:23 ratio showed similar effi-
cacy of lowering blood glucose as insulin alone. Thus, there
was no glucagon-effect with low doses of the 1:23 ratio
(<0.9 nmol/kg glucagon-analogue). It is essential to avoid
significantly increased circulating insulin levels after dual
treatment with insulin and glucagon compared to insulin
treatment alone. Since insulin is also a growth factor and is
associated with weight gain an increased insulin dose is
unwanted for diabetic patients. In this study, the glucagon-
effect appeared right before hypoglycemia occurred. This
might be explained by the glucose-dependent actions of
glucagon. During euglycemia, it has been demonstrated
that insulin is a potent inhibitor of glucagon’s action on
the liver (Steiner et al. 1990). During hypoglycemia, gluca-
gon has been shown to significantly stimulate hepatic glu-
cose production, despite a 35-fold increase in insulin
(Dobbins et al. 1991). Furthermore, a direct comparison of
glucagon-action during euglycemia and hypoglycemia also
concludes that the hepatic sensitivity to glucagon is
increased during insulin-induced hypoglycemia (Rivera
et al. 2010). Overall indicating that, in the hypoglycemic
state, glucagon is able to overcome the inhibitory effect of
insulin on hepatic glucose production. The insulin-dose
resulting in hypoglycemia was increased from 40 nmol/kg
insulin alone to 160 nmol/kg insulin in the 1:23 ratio.
These data indicate that, compared with insulin alone, the
therapeutic window was increased four times when admin-
istering a fixed 1:23 ratio of glucagon and insulin. Impor-
tantly, analysis of the liver glycogen content at the end of
the experiment showed that the highest dose in the 1:23
ratio (7 nmol/kg glucagon-analogue + 160 nmol/kg insu-
lin) almost emptied the glycogen stores from the liver
(Fig. 7). This explains why glucagon was not able to protect
against hypoglycemia with this dose in the 1:23 ratio. Previ-
ously, a study in dogs has shown a correlation between the
hepatic glucose output in response to insulin-induced
hypoglycemia and glycogen content in the liver (Winnick
et al. 2016). Also, the glucagon effect during hypoglycemia
has been shown to be dependent on the preceding carbohy-
drate intake (Ranjan et al. 2017). For 1 week, patients with
type 1 diabetes had either a high-carbohydrate diet or a
low-carbohydrate diet. The glucagon-effect was evaluated
by administration of 100 lg glucagon after mild insulin-
induced hypoglycaemia (plasma glucose at 3.9 mmol/L).
Even though, glycogen stores were not measured it is very
likely that low carbohydrate intake reduced the glycogen
stores and thus caused the reduced glycemic response to
glucagon. Taken together, this indicates a higher risk of
developing hypoglycemia when less glycogen is available.
We do not intend to treat with a dose emptying the liver
from glycogen. We aim for a treatment that provides pro-
tection against hypoglycemia if overdosed. Another impor-
tant note is that our experiments were performed without
food present. Access to food will indeed increase the liver
glycogen content. More studies are needed to investigate
the glucagon-effect after multiple dosing and in the pres-
ence of food. In addition, it would be relevant to consider
the effect of other counterregulatory hormones for the
complete understanding of the protective mechanisms dur-
ing hypoglycemia.
In summary, these data support the hypothesis that a
fixed ratio of insulin and a long-acting glucagon-analogue
can reduce the risk of hypoglycemia. We have shown that a
1:23 ratio of the glucagon-analogue and insulin increases
the therapeutic window of insulin in diabetic rats. Impor-
tantly, this was obtained without compromising the
potency of insulin in the dose-range normalizing blood glu-
cose. If this can be translated to humans it is very likely to
improve the glycemic control for the diabetic patients.
With less fear of hypoglycemia, the patients will be able to
adhere to tighter glycemic control and thereby reduce the
risk of developing diabetic complications later in life. How-
ever, it is important to bear in mind the preliminary nature
of these findings as well as the limitations of the study to
fully clarify the clinical benefits. For instance, the liver
glycogen content was found to be essential for the protec-
tive effect of glucagon in hypoglycemia. Additional studies
are needed to assess whether glycogen content is a limiting
factor after multiple dosing with the fixed ratio of glucagon
and insulin. Moreover, this study was performed on STZ-
induced diabetic rats, which is considered as a type 1 dia-
betic animal model. It will be relevant to study the fixed
ratio of glucagon and insulin in a type 2 diabetic animal
model where a higher insulin dose is needed because of
more insulin resistance. Additionally, a type 2 diabetic ani-
mal model can be used to address potential anti-obesity
effects of glucagon (Parker et al. 2013).
Acknowledgment
We appreciate and thank Jens Juul Holst for fruitful dis-
cussions. We wish to thank Karen Arevad for excellent
technical assistance, and Rikke Sanggaard Ingvorsen and
Betina Bonnichsen for isolating and providing primary
rat hepatocytes. We furthermore thank Merete Achen,
Janni Estvan, Pernille Keller Andersen, Maria Bjerremann
2018 | Vol. 6 | Iss. 6 | e13657
Page 8
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
A Fixed Ratio of Glucagon and Insulin C. Pedersen et al.
Rasmussen, Trine Rørmose Løjmand, Marianne Bojsen
Jappe, and Emilie Due Jensen for invaluable assistance
during in vivo experiments.
Conflict of Interest
C. P., S. D. B., T. P., and N. K. R. are employed by Novo
Nordisk A/S.
References
Anderbro, T., L. Gonder-Frederick, J. Bolinder, P.-E. Lins, R.
Wredling, E. Moberg, et al. 2015. Fear of hypoglycemia:
relationship to hypoglycemic risk and psychological factors.
Acta Diabetol. 52:581–589.
Andersen, B., A. Rassov, N. Westergaard, and K. Lundgren. 1999.
Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-
dideoxy-1,4-imino-D-arabinitol. Biochem. J. 342:545–550.
Bomboy, J. D., S. B. Lewis, B. C. Sinclair-Smith, W. W. Lacy,
and J. E. Liljenquist. 1977. Insulin-glucagon interaction in
controlling splanchnic glucose production in normal man. J.
Clin. Endocrinol. Metab. 44:474–480.
Cherrington, A. D. 1999. Control of glucose uptake and release
by the liver in vivo. Diabetes 48:1198–1214.
Cherrington, A. D., J. L. Chiasson, and J. E. Liljenquist. 1976.
The role of insulin and glucagon in the regulation of basal
glucose production in the postabsorptive dog. J. Clin.
Investig. 58:1407–1418.
Christophe, J. 1995. Glucagon receptors: from genetic structure
and expression to effector coupling and biological responses.
Biochem. Biophys. Acta. 1241:45–57.
Cryer, P. E. 1993. Glucose counterregulation: prevention and
correction of hypoglycemia in humans. Am. J. Physiol. 264:
E149–E155.
Cryer, P. E. 2002. Hypoglycaemia: the limiting factor in the
glycaemic management of type I and type II diabetes.
Diabetologia 45:937–948.
Cryer, P. E., S. N. Davis, and H. Shamoon. 2003.
Hypoglycemia in diabetes. Diabetes Care 26:1902–1912.
Dobbins, R. L., C. C. Connolly, D. W. Neal, L. J. Palladino, A.
F. Parlow, and A. D. Cherrington. 1991. Role of glucagon in
countering hypoglycemia induced by insulin infusion in
dogs. Am. J. Physiol. 261:E773–E781.
El-khatib, F. H., S. J. Russell, D. M. Nathan, R. G. Sutherlin, and
E. R. Damiano. 2010. A bihormonal closed-loop artificial
pancreas for type 1 diabetes. Sci. Transl. Med. 2:27ra27.
Group IHS. 2016. Glucose concentrations of less than
3.0 mmol/L (54 mg/dL) should be reported in clinical trials:
a joint position statement of the American Diabetes
Association and the European Association for the study of
diabetes. Diabetes Care 40:155.
Haidar, A., L. Legault, M. Dallaire, A. Alkhateeb, A. Coriati, V.
Messier, et al. 2013. Glucose-responsive insulin and
glucagon delivery (dual-hormone artificial pancreas) in
adults with type 1 diabetes: a randomized crossover
controlled trial. CMAJ 185:297–305.
Ismail-Beigi, F., T. Craven, M. A. Banerji, J. Basile, J. Calles, R.
M. Cohen, et al. 2010. Effect of intensive treatment of
hyperglycaemia on microvascular outcomes in type 2
diabetes: an analysis of the ACCORD randomised trial.
Lancet 376:419–430.
Jiang, G., and B. B. Zhang. 2003. Glucagon and regulation of
glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284:
E671–E678.
Keith, NF. 2010. Metabolic regulation: a human perspective.
John Wiley & Sons, NJ, USA.
Khunti, K., M. Davies, A. Majeed, B. L. Thorsted, M. L.
Wolden, and S. K. Paul. 2015. Hypoglycemia and risk of
cardiovascular disease and all-cause mortality in insulin-
treated people with type 1 and type 2 diabetes: a cohort
study. Diabetes Care 38:316–322.
K€onig, M., S. Bulik, H. G. Holzh€utter. 2012. Quantifying the
contribution of the liver to glucose homeostasis: a detailed
kinetic model of human hepatic glucose metabolism. PLoS
Comput. Biol. 8:e1002577.
Mackrell, D. J., J. E.Sokal. 1969. Antagonism between the
effects of insulin and glucagon on the isolated liver.
Diabetes 18:724–732.
Parker, J. A., K. A. McCullough, B. C. T. Field, J. S. Minnion,
N. M. Martin, M. A. Ghatei, et al. 2013. Glucagon and
GLP-1 inhibit food intake and increase c-fos expression in
similar appetite regulating centres in the brainstem and
amygdala. Int. J. Obes. 37:1391–1398.
Ranjan, A., S. Schmidt, C. Damm-Frydenberg, I. Steineck, T.
R. Clausen, J. J. Holst, et al. 2017. Low-carbohydrate diet
impairs the effect of glucagon in the treatment of insulin-
induced mild hypoglycemia: a randomized crossover study.
Diabetes Care 40:132–135.
Rivera, N., C. J. Ramnanan, Z. An, T. Farmer, M. Smith, B.
Farmer, et al. 2010. Insulin-induced hypoglycemia increases
hepatic sensitivity to glucagon in dogs. J. Clin. Investig.
120:4425–4435.
Seglen, P. O. 1976. Preparation of isolated rat liver cells.
Methods Cell Biol. 13:29–83.
Sprague, J. E., and A. M. Arbelaez. 2011. Glucose
counterregulatory responses to hypoglycemia. Pediatr.
Endocrinol. Rev. 9:463–475.
Steiner, K. E., P. E. Williams, W. W. Lacy, and A. D. Cherrington.
1990. Effects of insulin on glucagon-stimulated glucose
production in the conscious dog. Metabolism 39:1325–1333.
Ward, W. K., J. Engle, H. M. Duman, C. P. Bergstrom, S. F.
Kim, and I. E. Federiuk. 2008. The benefit of subcutaneous
glucagon during closed-loop glycemic control in rats with
type 1 diabetes. IEEE Sens. J. 8:89–96.
Winnick, J. J., G. Kraft, J. M. Gregory, D. S. Edgerton, P.
Williams, I. A. Hajizadeh, et al. 2016. Hepatic glycogen can
regulate hypoglycemic counterregulation via a liver-brain
axis. J. Clin. Investig. 126:2236–2248.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 6 | e13657
Page 9
C. Pedersen et al. A Fixed Ratio of Glucagon and Insulin
